Skip navigation


Transforming the management of cancer with personalized testing

Signatera is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools

Knowing earlier matters

Each person’s cancer is as unique as their fingerprint. Signatera is a MRD blood test that is personalized to each patient’s set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.


How Signatera helps patients through their treatment

Living scan to scan can sometimes create anxiety for patients. The question of relapse looms in the back of their mind: Did the treatment work? Is the cancer coming back?

Through shared decision making, patients can work closely with their care team to incorporate Signatera into their treatment plan to provide additional information for confident decision making. Listen to Brooks Bell tell her story of how she achieved peace of mind between scans using Signatera.

Finding reassurance with Signatera

After JoAnn was diagnosed with lung cancer, she learned how Signatera could help her doctor detect potential disease progression ahead of scans. As part of her cancer monitoring plan, she received Signatera testing at regular intervals, helping her and her doctor make critical decisions. Learn how Signatera helped JoAnn and her family stay confident and positive throughout her treatment journey.

Signatera is a great warning system that something is going on. From there, you figure out what it is. Signatera does empower me to be my own best advocate with my oncologists.


Living with lung cancer

Signatera is validated in multiple cancer types


I have colorectal cancer

If you have been diagnosed with colorectal cancer, learn more how to identify residual disease and detect relapse sooner with Signatera MRD testing


I am on immunotherapy

If you are undergoing immunotherapy and want to know how the Signatera MRD test can help monitor the effectiveness of your treatment


Is Signatera right for me?

If you have been diagnosed with cancer such as breast, ovarian, lung or melanoma and want to learn more how to identify residual disease and detect relapse sooner

Why Signatera?

Signatera is a blood MRD test used for cancer detection and surveillance. It is personalized for each patient. It is used for molecular residual disease assessment and for treatment response monitoring.
A doctor may order Signatera along with routine follow-up exams to determine whether:

  • There are signs of cancer remaining in the body
  • Treatment (e.g., chemotherapy, radiation) is working
  • The cancer is recurring

How Signatera Works: a personalized and tumor informed approach to MRD surveillance


A one-time analysis of both blood and tissue determines your unique set of tumor mutations.


The MRD test is custom-built and personalized just for you, using your own tumor tissue.


Signatera MRD test detects small fragments of ctDNA each time it is ordered as part of your routine follow-up blood tests. Patients who are ctDNA positive by Signatera are more likely to relapse.

Understanding your Signatera test results

Your test results will either be positive or negative for the presence of tumor DNA in your blood. Your doctor will receive the test report and will be able to discuss your results and answer questions. These results provide additional insights and may help guide your treatment plan.
IMPORTANT: Negative ctDNA results may change over time. A negative MRD test result doesn’t guarantee that cancer will never be detected in the future. This is why ongoing monitoring with the Signatera test, as directed by your doctor, is recommended—for early detection of residual disease
Negative result
A negative result indicates that tumor DNA was not detected in your blood and that you are more likely to remain cancer-free if you were diagnosed with early stage cancer.
If you have metastatic cancer, a negative result may mean that your treatment was able to decrease the amount of cancer cells to undetectable levels, meaning the treatment has been effective.
Positive result
A positive result indicates that tumor DNA has been detected in your blood and means there is higher risk for your cancer returning if you were diagnosed with early-stage cancer. Your doctor may continue to monitor your ctDNA levels to assess your tumor’s response to treatment.

Is Signatera right for you?

We’re here to help you find out